Open Label Single Arm Study to Assess the Implementation of Home Based Daratumumab Administration in Patients Being Treated for Multiple Myeloma
Latest Information Update: 30 May 2025
At a glance
- Drugs Daratumumab/hyaluronidase (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
Most Recent Events
- 22 May 2025 Status changed from active, no longer recruiting to completed.
- 07 Feb 2024 Planned End Date changed from 1 Jan 2025 to 8 Nov 2025.
- 07 Feb 2024 Planned primary completion date changed from 1 Jan 2024 to 8 Jan 2025.